Citations

Clear

1727 citation(s) found for "So, Alan".

Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).
Parulekar, Wendy R. , Shepherd, Lois E. , Ligibel, Jennifer A. , Rastogi, Priya , Hobday, Timothy J. , Thompson, Alastair M. , Whelan, Timothy J. , Mukherjee, Som D., Chalchal, Haji , Oja, Conrad D., Tonkin, Katia, Bernstein, Vanessa , Goodwin, Pamela J. , Gelmon, Karen A. , Hershman, Dawn L. , Mayer, Ingrid A. , Lemieux, Julie , Pritchard, Kathleen I. , Chen, Bingshu E. , Stambolic, Vuk , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 1033-1033

10.1200/jco.2013.31.15_suppl.1033 Get It

1033 Background: MA.32 investigates effects of Metformin vs. Placebo, in addition to standard care, on invasive disease free survival and other outcomes. Metformin may improve obesity and metabolic factors [insulin, glucose, leptin, C-reactive protein (CRP)] that have been associated with poor BC outcomes. Maintaining blinding of investigators to outcomes, we conducted a planned, DSMB approved, analysis of the effect of Metformin vs. Placebo on weight and metabolic factors at 6 months, including examination of interactions with baseline body mass index (BMI), in the first 498 subjects with paired fasting plasma samples. Methods: 498 non-diabetic subjects with T1-3, N0-3, M0 BC meeting defined entry criteria who had completed surgery and adjuvant chemo (if given) provided fasting blood samples at randomization and 6 months (while on study drug). Glucose was measured locally; blood was aliquoted, frozen and stored at -80°C then shipped to NCIC CTG (Kingston, Canada). Paired plasma aliquots were shipped to Mount Sinai Hospital (Toronto, Canada) for analysis of Insulin (Dako), hsCRP (Roche Elecsys) and leptin (Luminex). Statistical analysis used the Wilcoxon signed rank test. Results: Mean age was 52.4 ±9.2 years. Arms were balanced for ER/PgR (63% pos), BMI, prior adjuvant chemo (89%), T and N status, grade, mastectomy/lumpectomy and radiation. Conclusions: Metformin significantly improved weight, insulin, glucose, leptin and CRP at 6 months. Effects did not vary by baseline BMI. Funded by: NIH, CCSRI, CBCF, BCRF, Apotex Canada (drug & placebo - in kind). Clinical trial information: NCT01101438. [Table: see text]
Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance).
Barton, Debra L. , Sloan, Jeff A. , Novotny, Paul J. , Fuloria, Jyotsna, Kottschade, Lisa A. , Lyss, Alan P., Jaslowski, Anthony J., Mazurczak, Miroslaw, Blair, Scott C., Terstriep, Shelby A., Loprinzi, Charles L.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 9513-9513

10.1200/jco.2013.31.15_suppl.9513 Get It

9513 Background: The need for more research in N/V control is exemplified by agents that are costly, interfere with cytochrome P450 metabolism, and inadequately address delayed N/V. Based on pilot data, there was justification for evaluating whether gabapentin could improve the prevention of delayed N/V from highly emetogenic chemotherapy (HEC). Methods: Patients (pts) about to receive HEC were randomized to prophylactic treatment with 20 mg of dexamethasone (dex) and a 5HT3 receptor antagonist (RA) on the day of chemotherapy, followed by either gabapentin (gaba) 300 mg BID and dex or placebo (plac) and dex. Gaba/plac was started the evening of the day of chemotherapy and continued through day 5 of the first chemotherapy cycle. Dex was given at 8 mg BID days 2-3, then 4 mg BID for day 4, in both arms. The primary endpoint was complete response (CR), defined as no emesis and no rescue medications day 2-6, using a nausea and vomiting diary. The percent of CR were compared in each group by Fisher’s exact test. Secondary outcomes included the Functional Living Index-Emesis (FLIE), satisfaction, and a side effect questionnaire. Results: 430 pts were enrolled in this study between 5/2009 and 2/2011. 47% of pts in the gaba arm and 41% in the plac arm had a CR (p=.23). At some time during days 2-6, 30% in the gaba and plac arms experienced emesis, and 45% and 53% in the gaba and plac arms, respectively, took rescue medication. Mean diary nausea scores over days 2-6 ranged from 0.9 – 1.2 (gaba arm) and 1.0-1.3 (plac arm)(7 = the worst); mean number of diary emetic episodes ranged from 0.1 -0.3 (gaba arm) and 0.1-0.2 (plac arm). The FLIE was not significantly different between arms. Mean vomiting satisfaction was 9.1 in both arms and for nausea was 8.3 for gaba, 8.1 for plac (10= totally satisfied). There were no significant differences in toxicities by CTCAE provider grading or by self-report. Conclusions: In this study, gaba did not improve delayed N/V. Overall, there was little emesis and nausea severity was low. Patients were satisfied with the control of their N/V, irrespective of arm. The use of standard prophylactic guidelines that include a 5HT3RA and dex provided good control of N/V for most patients. Clinical trial information: NCT00880191.
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic bre
Barry, William T., Moreno‐Aspitia, Alvaro , Lyss, Alan P., Cirrincione, Constance, Somer, Robert A. , Perez, Edith A. , Hudis, Clifford A. , Rugo, Hope S. , Mayer, Erica L. , Naughton, Michael J. , Layman, Rachel M. , Carey, Lisa A. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: CRA1002-CRA1002

10.1200/jco.2012.30.15_suppl.cra1002 Get It

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results
Hollis, Donna, Sutherland, Susan , Goldberg, Richard M. , Benson, Al B. , Wade, James L. , Schilsky, Richard L. , Mayer, R. John, Venook, Alan P. , Niedzwiecki, Donna , Alberts, Steven R. , Mayer, R.

Mayo Clinic

Journal of Clinical Oncology | March 9, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 3509-3509

10.1200/jco.2006.24.18_suppl.3509 Get It

3509 Background: FOLFIRI or FOLFOX are 1st-line treatments (Rx) for MCRC. Cetuximab is an IgG1 Mab that targets the epidermal growth factor receptor (EGFR) and is approved as monotherapy or in combination with irinotecan in irinotecan-refractory, EGFR + pts with MCRC. CALGB 80203 randomized untreated MCRC pts to FOLFOX or FOLFIRI ± cetuximab (independent of EGFR status.) Methods: Pts with performance status 0–1 with tumor blocks available for EGFR analysis received either irinotecan 180 mg/m2 over 1.5 hours (h) or oxaliplatin 85 mg/m2 over 2h combined with LV 400 mg/m2 over 2h and 5FU 400 mg/m2 bolus, then 46–48h CI 5FU 2400 mg/m2 q o w. Cetuximab dose: 400 mg/m2 loading dose, then 250 mg/m2 qw. Rx continued until progression or toxicity; subsequent Rx was not mandated although information was collected on such rx. Accrual goal was 2200 pts with intended 1° endpt of overall survival (OS). 80203 closed administratively in 1/05 (due to slow accrual) with 238 pts accrued. 2° endpts of response rate (RR), progression free survival (PFS), duration of R and toxicity are now able to be analyzed. Results: Accrual: FOLFIRI (A) - 61; FOLFIRI + cetuximab (B) - 59: FOLFOX (C) - 60; FOLFOX + cetuximab (D) - 58; approx median follow-up (f/u) is 12 months. RR (CR + PR, not all yet confirmed): A - 34%; B - 42%; C - 32%; D - 55%. RR was similar in the FOLFIRI or FOLFOX arms (A+B v. C+D; 38% v. 43%, p=0.44; chi-square) while C225 containing arms (B+D) v. non-C225 arms (A+C) had a superior RR (49% v. 33%; p=0.014, chi-square) It is too early to tell if there are differences in PFS, duration of response or OS. No significant differences in gr III diarrhea or any gr IV toxicities were seen. Conclusions: These results suggest that FOLFIRI and FOLFOX are similar in efficacy for pts with untreated MCRC and that adding cetuximab to either in1st-line Rx appears to increase response rates. PFS and duration of response do not appear different at this analysis. Further f/u and an analysis of prospective companion correlative studies may help to further clarify these results. [Table: see text]
Cytogenetic analysis using multiple myeloma targets in POEMS syndrome
Kyle, Robert A. , Lust, John A., Lacy, Martha Q. , Greipp, Philip R., Witzig, TE, Bryce, Alan H. , Ketterling, Rhett P. , Gertz, Morie A. , Fonseca, Rafaël , Witzig, T.E. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 25 | Issue: 18_suppl | Pages: 8116-8116

10.1200/jco.2007.25.18_suppl.8116 Get It

8116 Background: POEMS syndrome, or osteosclerotic myeloma, is an uncommon plasma cell disorder associated with Peripheral neuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes, as well as bone lesions, Castlemans disease, and edema. The pathogenesis of POEMS is poorly understood, and its clinical course is distinct from Multiple Myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). While various cytogenetic abnormalities have been well described in MM and MGUS, we provide the first report of testing for these abnormalities in POEMS syndrome. Methods: Using a prospectively held dysproteinemia database, we reviewed all cases of POEMS seen at our institution, identifying 36 with metaphase cytogenetic testing results, and 9 with fluorescence in situ hybridization (FISH) testing results. Combined cytoplasmic immunoglobulin/FISH testing (cIg- FISH) was performed with fluorescent-tagged antibodies to kappa/lambda immunoglobulin and FISH probes corresponding to the following anomalies: trisomies 3, 7, 9, 11, 15 and 17; del13/del13q; 14q32 split/del14; and t(11;14). Results: Five patients had insufficient plasma cells for cIg-FISH, and 9 were adequate for testing. Monosomy 13 was seen in 5 of the 9 cIg-FISH samples of which 2 of these cases also had apparent monosomy 14. cIg-FISH in one patient revealed trisomy 3 and 7. No abnormalities were seen at 11q13 (CCND1), 17p13 (p53) or translocations involving 14q32 (IGH). Thrity-eight total karyotypes analyses were attempted, though two showed an insufficient number of suitable metaphases. Of the 36 karyotype analyses, 31 were normal, 2 displayed characteristic plasma cell anomalies (hyperdiploid with structural anomalies), 2 treated patients displayed del20q anomalies and 1 patient had a constitutional 13;14 translocation. Conclusion: We are the first to report del13 as a possibly common abnormality in POEMS syndrome, detected by cIg-FISH in 5 of 9 (55%) samples with sufficient plasma cells, similar to the rate observed in MM and MGUS. The lack of abnormalities at 14q32 (IgH locus) is in contrast to MM and MGUS. Abnormal karyotypes, consistent with dividing plasma cells, are rare in POEMS, observed in only 2 of 36 (5.5%) cases. These observations could possibly lend insight into all three disorders. No significant financial relationships to disclose.
Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals
Leisman, Daniel E. , Harhay, Michael O., Adjei, Alex A. , Bakker, Jan , Barreiro, Esther , Bell, Scott C. , Bernstein, Jonathan A. , Branson, Richard D. , Brusasco, Vito , Chalmers, James D. , Chokroverty, Sudhansu , Citerio, Giuseppe , Collop, Nancy A. , Cooke, Colin R. , Crapo, James D. , Donaldson, Gavin C. , Grainger, Emma, Herth, Felix , Marks, Guy B. , Moorman, J. Randall , Ost, David E. , Schätz, Michael , Smyth, Alan R , Stewart, Iain , Stewart, Paul W. , Swenson, Erik R. , Szymusiak, Ronald , Wedzicha, Jadwiga A. , Ost, David E , Bakker, Jan , Marks, Guy B , Chalmers, James D , Harhay, Michael Oscar , Lederer, David J. , Abramson, Michael John , Ballas, Zuhair K. , Bellomo, Rinaldo , Fitzgerald, Dominic A. , Hale, Lauren E. , Kochanek, Patrick Michael , Sheikh, Aziz , Teboul, Jean–Louis , Vincent, Jean‐Louis , Maslove, David M.

Mayo Clinic

Critical Care Medicine | March 6, 2020 | Volume: 48 | Issue: 5 | Pages: 623-633

10.1097/ccm.0000000000004246 | PMID 32141923 Get It

Prediction models aim to use available data to predict a health state or outcome that has not yet been observed. Prediction is primarily relevant to clinical practice, but is also used in research, and administration. While prediction modeling involves estimating the relationship between patient factors and outcomes, it is distinct from casual inference. Prediction modeling thus requires unique considerations for development, validation, and updating. This document represents an effort from editors at 31 respiratory, sleep, and critical care medicine journals to consolidate contemporary best practices and recommendations related to prediction study design, conduct, and reporting. Herein, we address issues commonly encountered in submissions to our various journals. Key topics include considerations for selecting predictor variables, operationalizing variables, dealing with missing data, the importance of appropriate validation, model performance measures and their interpretation, and good reporting practices. Supplemental discussion covers emerging topics such as model fairness, competing risks, pitfalls of “modifiable risk factors”, measurement error, and risk for bias. This guidance is not meant to be overly prescriptive; we acknowledge that every study is different, and no set of rules will fit all cases. Additional best practices can be found in the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines, to which we refer readers for further details.
Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts
D’Amico, Thomas A., Bandini, Lindsey, Balch, Alan , Benson, Al B. , Edge, Stephen B. , Fitzgerald, Clara , Green, Robert J. , Koh, Wui-Jin, Kolodziej, Michael , Kumar, Shaji , Meropol, Neal J. , Mohler, James L. , Pfister, David G. , Walters, Ronald S., Carlson, Robert W. , Fitzgerald, C. Lyn, Green, Robert J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 250-259

10.6004/jnccn.2020.7536 | PMID 32135508 Get It

Although oncology care has evolved, outcome assessment remains a key challenge. Outcome measurement requires identification and adoption of a succinct list of metrics indicative of high-quality cancer care for use within and across healthcare systems. NCCN established an advisory committee, the NCCN Quality and Outcomes Committee, consisting of provider experts from NCCN Member Institutions and other stakeholders, including payers and patient advocacy, community oncology, and health information technology representatives, to review the existing quality landscape and identify contemporary, relevant cancer quality and outcomes measures by reevaluating validated measures for endorsement and proposing new measure concepts to fill crucial gaps. This manuscript reports on 22 measures and concepts; 15 that align with existing measures and 7 that are new.
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
Hwang, E. Shelley , Hyslop, Terry , Hendrix, Laura H., Duong, Stephanie Q. , Price, Elissa R. , Caudle, Abigail S. , Guenther, Joseph M., Hudis, Clifford A. , Lyss, Alan P., Dickson-Witmer, Diana , Ollila, David W. , Hardman, Timothy, Marks, Jeffrey R. , Chen, Yunn-Yi, Krings, Gregor , Esserman, Laura J. , Duong, Stephanie, Hieken, Tina, Esserman, Laura J , Bedrosian, Isabelle , Hieken, Tina J. , Winer, Eric P. , Hoefer, Richard, Chen, Yunn‐Yi , Hylton, Nola M.

Mayo Clinic

Journal of Clinical Oncology | March 3, 2020 | Volume: 38 | Issue: 12 | Pages: 1284-1292

10.1200/jco.19.00510 | PMID 32125937 Get It

PURPOSE Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied. This trial explored the feasibility of a short-term course of letrozole and sought to determine whether treatment results in measurable radiographic and biologic changes in estrogen receptor (ER)–positive DCIS. PATIENTS AND METHODS A phase II single-arm multicenter cooperative-group trial was conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion. Patients were treated with letrozole 2.5 mg per day for 6 months before surgery. Breast magnetic resonance imaging (MRI) was obtained at baseline, 3 months, and 6 months. The primary end point was change in 6-month MRI enhancement volume compared with baseline. RESULTS Overall, 79 patients were enrolled and 70 completed 6 months of letrozole. Of these, 67 patients had MRI data available for each timepoint. Baseline MRI volumes ranged from 0.004 to 26.3 cm 3 . Median reductions from baseline MRI volume (1.4 cm 3 ) were 0.6 cm 3 (61.0%) at 3 months ( P < .001) and 0.8 cm 3 (71.7%) at 6 months ( P < .001). Consistent reductions were seen in median baseline ER H-score (228; median reduction, 15.0; P = .005), progesterone receptor H-score (15; median reduction, 85.0; P < .001), and Ki67 score (12%; median reduction, 6.3%; P = .007). Of the 59 patients who underwent surgery per study protocol, persistent DCIS remained in 50 patients (85%), invasive cancer was detected in six patients (10%), and no residual DCIS or invasive cancer was seen in nine patients (15%). CONCLUSIONS In a cohort of postmenopausal women with ER-positive DCIS, preoperative letrozole resulted in significant imaging and biomarker changes. These findings support future trials of extended endocrine therapy as primary nonoperative treatment of some DCIS.
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria
Kardashian, Ani , Haydel, Brandy , Ruiz, Richard , Klintmalm, Göran B. , Lee, David D. , Aucejo, Federico , Tevar, Amit D. , Humar, Abhinav , Verna, Elizabeth C. , Halazun, Karim J. , Vachharajani, Neeta , Nguyen, Mindie H. , Melcher, Marc L. , Langnas, Alan N. , Carney, Carol A., Mobley, Constance M. , Ghobrial, R. Mark , Amundsen, Beth, Markmann, James F. , Sudan, Debra L. , Jones, Christopher M. , Berumen, Jennifer , Hemming, Alan W. , Hong, Johnny C. , Kim, Joohyun , Zimmerman, Michael A. , Nydam, Trevor L. , Rana, Abbas , Kueht, Michael , Fishbein, Thomas , Markovic, Daniela , Busuttil, Ronald W. , Lee, David D , Taner, C. Burcin , Kim, Joohyun , Busuttil, Ronald W , Agopian, Vatche G , Melcher, Marc L , Halazun, Karim J , Sudan, Debra L , Florman, Sander , Chapman, William C. , Hoteit, Maarouf , Levine, Matthew H , Agopian, Vatche G.

Mayo Clinic

Hepatology | March 3, 2020 | Volume: 72 | Issue: 6 | Pages: 2014-2028

10.1002/hep.31210 | PMID 32124453 Get It

Background and Aims The Organ Procurement and Transplantation Network recently approved liver transplant (LT) prioritization for patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are down‐staged (DS) with locoregional therapy (LRT). We evaluated post‐LT outcomes, predictors of down‐staging, and the impact of LRT in patients with beyond‐MC HCC from the U.S. Multicenter HCC Transplant Consortium (20 centers, 2002‐2013). Approach and Results Clinicopathologic characteristics, overall survival (OS), recurrence‐free survival (RFS), and HCC recurrence (HCC‐R) were compared between patients within MC (n = 3,570) and beyond MC (n = 789) who were down‐staged (DS, n = 465), treated with LRT and not down‐staged (LRT‐NoDS, n = 242), or untreated (NoLRT‐NoDS, n = 82). Five‐year post‐LT OS and RFS was higher in MC (71.3% and 68.2%) compared with DS (64.3% and 59.5%) and was lowest in NoDS (n = 324; 60.2% and 53.8%; overall P < 0.001). DS patients had superior RFS (60% vs. 54%, P = 0.043) and lower 5‐year HCC‐R (18% vs. 32%, P < 0.001) compared with NoDS, with further stratification by maximum radiologic tumor diameter (5‐year HCC‐R of 15.5% in DS/<5 cm and 39.1% in NoDS/>5 cm, P < 0.001). Multivariate predictors of down‐staging included alpha‐fetoprotein response to LRT, pathologic tumor number and size, and wait time >12 months. LRT‐NoDS had greater HCC‐R compared with NoLRT‐NoDS (34.1% vs. 26.1%, P < 0.001), even after controlling for clinicopathologic variables (hazard ratio [HR] = 2.33, P < 0.001) and inverse probability of treatment‐weighted propensity matching (HR = 1.82, P < 0.001). Conclusions In LT recipients with HCC presenting beyond MC, successful down‐staging is predicted by wait time, alpha‐fetoprotein response to LRT, and tumor burden and results in excellent post‐LT outcomes, justifying expansion of LT criteria. In LRT‐NoDS patients, higher HCC‐R compared with NoLRT‐NoDS cannot be explained by clinicopathologic differences, suggesting a potentially aggravating role of LRT in patients with poor tumor biology that warrants further investigation.
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia
Sampson, Maureen , Ling, Clarence, Sun, Qian , Harb, Roa , Ashmaig, Mohmed, Warnick, Russell, Sethi, Amar A, Fleming, James K. , Otvos, James D. , Meeusen, Jeff W., Delaney, Sarah , Jaffe, Allan S. , Shamburek, Robert D., Amar, Marcelo , Remaley, Alan T. , Delaney, Sarah R, Meeusen, Jeffrey W. , Jaffe, Allan S.

Mayo Clinic

JAMA Cardiology | February 26, 2020 | Volume: 5 | Issue: 5 | Pages: 540

10.1001/jamacardio.2020.0013 | PMID 32101259 Get It